Skip to content

PERNIX THERAPEUTICS HOLDINGS, INC.

CIK 0001024126

← back to feed
Revenue (TTM)
$132.67M
+2.6% YoY Q3 Nov 2018
Net Income (TTM)
−$37.58M
−609.8% YoY Q3 Nov 2018
EPS Diluted (TTM)
−$3.17
−761.9% YoY Q3 Nov 2018
Gross Margin
98.0%
Q3 Nov 2018
Operating Margin
-17.4%
Q3 Nov 2018
Net Margin
-28.3%
Q3 Nov 2018
Free Cash Flow (TTM)
−$23.89M
Q3 Nov 2018
Cash
$24.51M
Q3 Nov 2018
Total Debt
$322.46M
Q3 Nov 2018
Shares Outstanding
14.51M sh
Q3 Nov 2018

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings